Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: An extended multicenter phase II study

Onkologie

Volumn 30, Issue 5, 2007, Pages 235-240

  Hartmann, Jörg Thomas ^a   Pintoffl, Jan Peter ^a   Al Batran, Salah Eddin ^b   Quietzsch, Detlef ^c   Meisinger, Ines ^a   Horger, Marius ^d   Nehls, Oliver ^a   Bokemeyer, Carsten ^a,f   Königsrainer, Alfred ^e   Jäger, Elke ^b   Kanz, Lothar ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b KRANKENHAUS NORDWEST   (Germany)

^c KLINIKUM CHEMNITZ   (Germany)

^d Abteilung Diagnostische Radiologie   (Germany)

^e Viszeral und Transplantationschirurgie

^f UNIVERSITY OF HAMBURG   (Germany)

Author keywords

5 Fluorouracil, continuous infusional; Gastric cancer, advanced; Mitomycin C; Phase II study; Salvage chemotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; METOCLOPRAMIDE; MITOMYCIN C; ONCOFOLIC; PLATINUM DERIVATIVE; PREDNISOLONE; SEROTONIN 2 ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 34247565177     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100828     Document Type: Article

References (25)

1. Moertel CG, Reitemeier RJ, Hahn RG: Mitomycin C therapy in advanced gastrointestinal cancer. JAMA 1968;204:1045-1048.
2. Moertel CG: Clinical management of advanced gastrointestinal cancer. Cancer 1975;36:675-682.
3. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004.
4. Hartmann JT, Harstrick A, Daikeler T, Kollmannsberger C, Muller C, Seeber S, Kanz L, Bokemeyer C: Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. Anticancer Drugs 1998;9:427-431.
5. Hartmann JT, Quietzsch D, Daikeler T, Kollmannsberger C, Mayer F, Kanz L, Bokemeyer C: Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anticancer Drugs 1999;10:729-733.
6. Hartmann JT, Oechsle K, Quietzsch D, Wein A, Hofheinz RD, Honecker F, Nehls O, Kohne CH, Kaefer G, Kanz L, Bokemeyer C: Protracted infusional 5-fluorouracil plus high dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. Br J Cancer 2003;89:2051-2056.
7. Chester JD, Dent JT, Wilson G, Ride E, Seymour MT: Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. Ann Oncol 2000;11:235-237.
8. Kretzschmar A, Reichardt P, Thuss-Patience PC, Hohenberger P, Benter T, Dorken B, Kohne CH: Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer. Oncology 2000;59:14-17.
9. Hofheinz RD, Hartung G, Samel S, Hochhaus A, Pichlmeier U, Post S, Hehlmann R, Queisser W: High-dose 5-fluorouracil/folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study. Onkologie 2002;25:255-260.
10. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R, Oates J: A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997;8:995-1001.
11. Chang HM, Jung KH, Kim TY, Kim WS, Yang HK, Lee KU, Choe KJ, Heo DS, Bang YJ, Kim NK: A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer. Ann Oncol 2002;13:1779-1785.
12. Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, Harper P, Maisey N, Mochlinski K, Prior Y, Hill M: A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 2002;13:1568-1575.
13. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-151.
14. Kaplan EL, Maier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
15. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168.
16. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
17. Wilke H, Korn M, Vanhofer U, Fink U, Stahl M, Preusser P, Kohne C, Klassen U, Harstrick A, Schmoll HJ, Seeber S: Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer. J Infus Chemother 1996;6:123-126.
18. Schnall S, Macdonald JS: Mitomycin therapy in gastric cancer. Oncology 1993;50(suppl 1):70-77.
19. Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Park K: Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br J Cancer 2005;92:1850-1854.
20. Jeung HC, Rha SY, Noh SH, Roh JK, Chung HC: A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. Cancer Chemother Pharmacol 2007;59:313-320.
21. Giuliani F, Molica S, Maiello E, Battaglia C, Gebbia V, Di Bisceglie M, Vinciarelli G, Gebbia N, Colucci G: Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). Am J Clin Oncol 2005;28:581-585.
22. Rudi J, Werle S, Bergtholdt D, Hofheinz RD: Infusional 5-fluorouracil and mitomycin C: an effective regimen in the treatment of advanced gastric cancer. Onkologie 2005;28:128-132.
23. Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, Arbus M, Woolley PV, Chiazze L, Schein PS: Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989;7:781-789.
24. Becker K, Rinas U, Weidmann B, Heider A, Niederle N: High-dose 5-fluorouracil/folinic acid plus mitomycin C in patients with refractory colorectal cancer. Proc Am Soc Clin Oncol 1997;16:283.
25. Hartmann JT, Kanz L, Bokemeyer C: Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma. Anticancer Res 2000;20:1177-1182.